MELISSA DELAFUENTE GONZALEZ: Open Payments
NPI 1306141312 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$748 in 30 payments from 12 companies in 2025. Trend: 2023 $64 · 2024 $489 · 2025 $748
Food & beverage: $748
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $244 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $149 |
| Dexcom, Inc. | 4 | $141 |
| Endologix LLC | 1 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
Products named: Ozempic, DEXCOM G7 GSS (161), ENDOCROSS Device, Kerendia, Rybelsus, JARDIANCE, SHINGRIX, REXULTI.
Industry payments across TX — which companies pay providers there.
